Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 35,776

Document Document Title
WO/2018/011569A1
The present invention relates to compounds that are useful as inhibitors of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compound...  
WO/2018/011162A1
The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R3 are as described above. The compounds may be useful for the treatment or prophylaxi...  
WO/2018/011164A1
The present invention relates to a compound of formula (I) wherein R1 is phenyl, lower alkyl, C3-6-cycloalkyl, -CH2-C3-6-cycloalkyl or bridged C4-6-cycloalkyl, substituted by one, two or three halogen atoms, or by lower alkyl or lower al...  
WO/2018/012780A1
Use of a mixture of compounds according to the present invention as a phosphorescent host material can achieve a high light emitting efficiency and a low driving voltage in an organic electric element. In addition, an organic electric el...  
WO/2018/011160A1
The present invention relates to compounds of the formula (I) or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R4 are as described above. The compounds may be useful for the treatment or prophylaxis...  
WO/2018/013862A1
Provided herein are compositions and methods for the treatment of a hematological malignancy. Also disclosed herein are compositions and methods for the treatment of Ewings Sarcoma. Said compositions comprise isoform selective pyrrolo-py...  
WO/2018/011229A1
The present invention relates to the use of complexes of water soluble porphyrins of formula (I). The present invention relates to water soluble porphyrins of formula (I), wherein R1 to R11 and R1' to R8' are as defined in claim 1, their...  
WO/2018/011681A1
Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, a...  
WO/2018/012781A1
Provided are an organic electronic element and an electronic device thereof, the organic electronic element being capable of achieving high light-emitting efficiency and a low driving voltage, and can also greatly improve the lifespan of...  
WO/2018/011163A1
The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R4 and Q are as described above. The compounds may be useful for the treatment or prop...  
WO/2018/013213A1
The invention relates to new compounds that reduce c-Myc expression and useful for cancer treatment, particularly hematological cancers such as aggressive B- and T-cell lymphomas. The new compounds may be combined with adjunct c-Myc inhi...  
WO/2018/011570A1
The present invention relates to compounds that are useful as inhibitors of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compound...  
WO/2018/009017A1
The present invention relates to 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical compositions containing the same, wherein the 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composit...  
WO/2018/009544A1
The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK...  
WO/2018/009625A1
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This inve...  
WO/2018/006870A1
Provided are a crystal A of Galunisertib and preparation method therefor and use thereof. The crystal form has favorable performance such as good stability and solubility, and low hygroscopicity, and is of great value for future optimiza...  
WO/2018/007331A1
The present invention relates to compounds of formula (I), wherein R1 is phenyl, lower alkyl, C3-6-cycloalkyl, -CH2-C3-6-cycloalkyl, or bridged C3-5-cycloalkyl, optionally substituted by one, two or three substituents, selected from halo...  
WO/2018/000550A1
Disclosed is a pyrazolo [3,4-d] pyrimidine derivative represented by the formula (I), having a significant inhibitory effect on tumour cells, and being used for the prevention or treatment of tumour-related diseases, particularly lung ca...  
WO/2018/002437A1
Compounds of formula (I): wherein Ra and Rb are as defined in the claims, exhibit alpha2C antagonistic activity and are thus useful as alpha2C antagonists.  
WO/2018/001331A1
The present invention relates to an imidazopyridinamine phenyl derivative, pharmaceutically acceptable salt thereof, hydrate or metabolite formed by metabolizing in any form, and use thereof in the preparation of a medicament for prevent...  
WO/2018/005881A1
Provided herein are compounds of formula (IA) and (III) useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in t...  
WO/2018/002958A1
The present invention relates to novel hydrazide containing compounds as Bruton tyrosine kinase inhibitors, process of preparation thereof, and to the use of the compounds in the preparation of pharmaceutical compositions for the therape...  
WO/2018/005192A1
Bifunctional compounds that increase uric acid excretion and reduce uric acid production, and monofunctional compounds that either increase uric acid excretion or reduce uric acid production. Methods of using these compounds for reducing...  
WO/2018/005860A1
This invention is in the area of pyrimidine-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.  
WO/2018/004306A1
The present invention relates to a pyrazolopyrirmidine derivative, or a pharmaceutically acceptable salt thereof. The compound according to the present invention can be usefully used for the prevention or treatment of diseases which are ...  
WO/2018/002848A1
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, azadecaline derivatives that possess unique antiviral activity are provided as HIV maturation inhibito...  
WO/2018/004258A1
The present invention relates to a novel heterocyclic derivative compound and a use thereof and, more particularly, to a novel heterocyclic derivative compound having selective inhibitory activity against a fibroblast growth factor recep...  
WO/2018/003976A1
In agricultural and horticultural crop production, etc., damage by pests and the like remains devastating even today, and due to factors such as the occurrence of pests resistant to existing chemicals, there is a demand for the developme...  
WO/2018/002219A1
Fused aromatic bicyclic substituted 5-(2-amino-4-pyrimidinyl)- cyanoindoline derivatives (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-KB-inducing kinase (NIK - also known as MAP3K14) useful...  
WO/2018/001330A1
Provided are porphyrin small molecules substitutes designed and synthesized for bulk hetero junction (BHJ) organic solar cells (OSOs). Provided are synthesized materials with strong and ordered self-assembly property, leading to form bic...  
WO/2018/001944A1
The present invention provides novel compounds having the general formula: wherein R1, R2, A and X are as described herein, compositions including the compounds and methods of using the compounds.  
WO/2018/005865A1
This invention is in the area of synthesizing pyrimidine-based compounds useful in the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.  
WO/2018/000250A1
Provided is a new ibrutinib crystal form and a preparation method therefor. Specifically, provided are an ibrutinib crystal form III and a preparation method therefor. The ibrutinib crystal form III prepared by the preparation method pro...  
WO/2017/221100A1
A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R3, R4, R6, and R7 are as defined herein.  
WO/2017/222976A1
Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders...  
WO/2017/219955A1
Provided are certain compounds or pharmaceutically acceptable salts thereof which can inhibit kinase activity of Bruton's tyrosine kinase (BTK) and may be useful for the treatment of diseases like cancer, immunological disease and inflam...  
WO/2017/223414A1
This application relates to compounds of Formula (I) or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, card...  
WO/2017/220477A1
The invention relates to N-(substituted-phenyl)-sulfonamide compounds, which are extremely useful as inhibitors of protein kinases (e.g. PERK kinase) and accordingly can be used for the treatment of cell proliferative disorders, such as ...  
WO/2017/220544A1
The invention relates to a compound of formula (I) wherein R wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.  
WO/2017/220431A1
Novel fused pyrazole derivatives of Formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).  
WO/2017/221135A1
Embodiments of the present disclosure provide compounds derived by Troger's amine as shown below, microporous structures, membranes, methods of making said compounds, structures, and membranes, methods of use for gas separation, and the ...  
WO/2017/223275A1
The present disclosure relates generally to derivatives of pyrrolobenzodiazepines and antibody-drug conjugates thereof and to methods of using these conjugates as therapeutics and/or diagnostics.  
WO/2017/223202A1
A compound of Formula II or a pharmaceutically acceptable salt thereof, wherein CyN is a cyclic amine group bound via a nitrogen atom; X is C or N; R1 and R2 are each independently a halogen, CN, CF3, CHF2, CH2F, a C1-C10alkyl group, a C...  
WO/2017/220516A1
The invention relates to a compound of formula (I) containing at least one diazirenyl. The compound of formula (I) is a type-2 cannabinoid (CB2) receptor modulator and can be used as a medicament.  
WO/2017/220517A1
The invention relates to a compound of formula (I) wherein R1 to R4 and n are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.  
WO/2017/219800A1
Selective mTOR inhibitors of formulas (I)-(III), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from abnormal cell growth, functions, or beh...  
WO/2017/223432A1
The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula (I), or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. (formula I) For Formula...  
WO/2017/219948A1
Provided herein are crystalline forms of a triazolopyrimidine compound, which is useful for treating a PRC2-mediated disease or disorder.  
WO/2017/218802A1
The disclosure is directed to compounds of Formula (I) and Formula (II). Methods of their use and preparation is other described.  
WO/2017/215588A1
Provided is a dihydropyrazole azepine compound serving as an Akt inhibitor; specifically disclosed is a compound as represented by formula (1) or a pharmaceutically acceptable salt thereof.  

Matches 1 - 50 out of 35,776